appScorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
HighStrong financials and growth story over the years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
News & Opinions
Vivanza Biosciences consolidated net profit declines 34.62% in the September 2022 quarter
1 year ago•Business Standard
Vivanza Biosciences consolidated net profit rises 23.81% in the September 2021 quarter
2 years ago•Business Standard
Vivanza Biosciences reports consolidated net profit of Rs 0.32 crore in the June 2021 quarter
3 years ago•Business Standard
Vivanza Biosciences reports consolidated net loss of Rs 0.13 crore in the March 2021 quarter
3 years ago•Business Standard
Vivanza Biosciences reports consolidated net profit of Rs 0.17 crore in the December 2020 quarter
3 years ago•Business Standard
Vivanza Biosciences reports standalone net profit of Rs 0.15 crore in the December 2020 quarter
3 years ago•Business Standard